|
|
| Antalgiques > Etude de marché sectorielle |
| Disease and Therapy Review: Migraine |
|
|
|
|
€ 720,00 |
Editeur
: |
Timely Data Resources |
Langue
: |
Anglais |
Date de publication : |
Février 2007 |
Taille du document : |
9 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Opioid Abuse - Hooked on Generics?
42 pages | Décembre 2005 |
IntroductionOpioid abuse is a growing medical challenge, yet few developments have been made in its treatment in recent years.
The market requires clarification of the goals of therapy - to remove |
3 230,00 €
|
| |
| |
U.S. Sales of Prescription Painkillers Classified as Narcotics, 1998-2010
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
UK Analgesics 2007
12 pages | Avril 2007 |
Snapdata's Snapshots UK Analgesics 2007 provides 2005 year-end market size data, with 2006 estimates, 4 years of historical data and five-year forecasts.
The Snapshots report gives an instant overv |
240,00 €
|
| |
| |
Disease and Therapy Review: Migraine
9 pages | Février 2007 |
The Migraine Disease and Therapy Review provides prevalence numbers and percentages for major countries worldwide.
Diagnosis of migraine is covered, along with information on treatment options for |
720,00 €
|
| |
| |
Drug Safety in the Post-Vioxx Era: New legislation, regulation and company strategies in Europe and the US
175 pages | Juillet 2005 |
The new report, Drug Safety in the Post-Vioxx Era: New legislation, regulation and company strategies in Europe and the US, examines the actions taken by legislative and regulatory bodies in response |
1 520,00 €
|
| |
| |
US State Market Index: Analgesics
12 pages | Juillet 2006 |
The metrics in this report cover three year trends in Analgesics [Manufacturing sector], broken out on a state-by-state basis.
Analysis is based on data applied from 7 industry firms.
Industry m |
475,00 €
|
| |
| |
Anesthesia Competitors
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
Event Analysis and Response Service: Cox-2s - Cox-2 Crisis Dents Big Pharma Confidence
95 pages | Juin 2005 |
IntroductionOn 30th September 2004, Merck withdrew its blockbuster drug Vioxx from the global market after trial data reinforced the suspicion that it increased the risk of cardiovascular events.
V |
9 120,00 €
|
| |
| |
Analgesics
651 pages | Janvier 2006 |
This report analyzes the worldwide markets for Analgesics in Millions of US$.
The major product segments analyzed are Internal Analgesics, and External Analgesics.
The sub-product segments discu |
2 699,00 €
|
| |
| |
OTC Analgesics in the United Kingdom
10 pages | Juin 2005 |
Euromonitor International’s ‘OTC Analgesics in the UK' Major Market Profile report offers an introduction to the market.
It is c.
10 pages long and provides a top line overview of sales trends |
198,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Disease and Therapy Review: Migraine |
|
|
The Migraine Disease and Therapy Review provides prevalence numbers and percentages for major countries worldwide. Diagnosis of migraine is covered, along with information on treatment options for prophylactic, symptomatic, and triptan therapy. Dosing for common prophylactic therapies is provided, along with dosing and treatment costs of triptan therapies. Market size estimates and annual sales of leading therapies are provided.
Disease and Therapy Reviews were developed to provide a basic understanding of the key facts about a disease and market in a quick, easy-to-read format. These reports are prepared by the senior market research team of Timely Data Resources. Each Disease and Therapy Review provides a concise analysis of the most important information about a particular disease, its treatment, and the market opportunities. Reports begin with an overview of the condition, and also contain tables that summarize the available worldwide incidence and prevalence data for the condition, a review of current diagnosis strategies and treatment options, general information about the market size, and information about important market trends. The data contained in these reports comes from key industry secondary data sources, such as the Timely Data Resources Incidence and Prevalence Database and Lange's Current Medical Diagnosis and Treatment. This information is supplemented by reviews of analyst reports, company reports, and medical websites. Sources and references are provided.
|
|
I. OVERVIEW
II. INCIDENCE AND PREVALENCE
Prevalence Table: (US, Canada, France, Italy, Japan, China, Worldwide)
Prevalence Notes on Severity and Frequency
III. DIAGNOSIS
Example of Diagnosis Criteria Using International Headache Society ICHD-II
IV. TREATMENT
Prophylactic Therapy
Table: Products Used in the Prophylactic Treatment of Migraine
Symptomatic Therapy
Symptomatic Therapy - Triptans
Treatment of Cluster Headache
V. DOSING AND TREATMENT COSTS
VI. MARKET SIZE
VII. COMMENTS
VIII. REFERENCES/RESOURCES
|
|
|
PPLSEN
|
|
|
|
|
